AstraZeneca Results Presentation Deck
BioPharmaceuticals:
'What's next'
Expanding pipeline, including immunology
What's next
Phase I/II new medicines, selected
MEDI3506
(IL33¹ mAb²)
DKD
cotadutide
(GLP-1/glucagon co-agonist)
NASH, DKD
AZD4831
(MPO inhibitor)
HFpEF
AZD5718
(FLAP inhibitor)
CKD, CAD
AZD9977 + Farxiga
(MCR modulator + SGLT2)
HF with CKD
zibotentan + Farxiga
(ETR³ antagonist + SGLT2)
CKD
CAD Plla
available
✓
MEDI3506
(IL33 mAb)
asthma, COPD, AD4, COVID-19
AZD1402
(IL4Ra5 antagonist)
asthma
AZD0449, AZD4604
(inhaled JAK6 inhibitors)
asthma
MEDI7352
(NGF7 TNF8 bispecific
fusion protein) - pain
AZD2693
(PNPLA3 inhibitor)
NASH
AZD8233
(PCSK9 ASO⁹)
hypercholesterolaemia
Phase II
started ✓
AZD4604
Phase I
started ✓
Phase II
started ✓
1. Interleukin-33 2. Monoclonal antibody 3. Endothelin receptor 4. Atopic dermatitis (eczema) 5. Interleukin-4 receptor alpha 6. Janus kinase 7. Nerve growth factor 8. Tumour
necrosis factor 9. Antisense oligonucleotide 10. Trial technically classified as Phase II.
30
What's now
Phase III new medicines
roxadustat
anaemia in CKD
nirsevimab
RSV
brazikumab
inflammatory bowel disease¹0
PT027
asthma
Farxiga
multiple indications
tezepelumab
severe asthma
anifrolumab
lupus (SLE)
Phase III lifecycle management, major
New
Phase III
started ✓
Fasenra
multiple indications
Breztri/Trixeo
asthmaView entire presentation